|
Status |
Public on Nov 22, 2019 |
Title |
Sample43_597854: D00000000206064_DAY 1_Tofacitinib |
Sample type |
protein |
|
|
Source name |
Blood_DAY 1_Tofacitinib
|
Organism |
Homo sapiens |
Characteristics |
visit: DAY 1 treatment: CP-690,550 10 mg BID treatmentshort: Tofacitinib pasi: 12 pasi.baseline: 12 pasi.week4: 10.2 pasi.week12: 7.3 tag: 39 pasi75.response: NR age: 29 gender: F platesimple: Plate3 plate: Plate3_CVD_A3921080_LOD
|
Treatment protocol |
Patients were treated with either tofacitinib 10mg QD or etanercept 50mg BIW as described in ClinicalTrials.gov: NCT01241591 and Bachelez et al., 2015
|
Extracted molecule |
protein |
Extraction protocol |
see manufacture protocol https://www.olink.com/content/uploads/2017/11/0935-v1.9.4-Proseek-Multiplex-User-Manual_final.pdf
|
Label |
oligonucleotide-labeled antibody
|
Label protocol |
see manufacture protocol https://www.olink.com/content/uploads/2017/11/0935-v1.9.4-Proseek-Multiplex-User-Manual_final.pdf
|
|
|
Hybridization protocol |
see manufacture protocol https://www.olink.com/content/uploads/2017/11/0935-v1.9.4-Proseek-Multiplex-User-Manual_final.pdf
|
Scan protocol |
Detection and quantification of the resulting DNA sequences was performed using microfluidic real-time quantitative PCR chip (96.96, Dynamic Array IFC, Fluidigm Biomark, South San Francisco, CA).
|
Data processing |
Detection and quantification of the resulting DNA sequences was performed using microfluidic real-time quantitative PCR chip (96.96, Dynamic Array IFC, Fluidigm Biomark, South San Francisco, CA).
|
|
|
Submission date |
Aug 27, 2019 |
Last update date |
Nov 22, 2019 |
Contact name |
Lewis Elwood Tomalin |
E-mail(s) |
l.tomalin1987@gmail.com
|
Organization name |
Icahn School of Medicine at Mount Sinai
|
Department |
Population Health Science & Policy
|
Street address |
303 East 71st Street, Apt1B
|
City |
New York |
State/province |
New York |
ZIP/Postal code |
10021 |
Country |
USA |
|
|
Platform ID |
GPL27151 |
Series (2) |
GSE136431 |
Early quantification of systemic inflammatory (INF) and cardiovascular disease (CVD) proteins predicts long-term treatment response to Tofacitinib and Etanercept (CVD data set) |
GSE136435 |
Early quantification of systemic inflammatory (INF) and cardiovascular disease (CVD) proteins predicts long-term treatment response to Tofacitinib and Etanercept |
|